According to a newly published meta-analysis: ”Individuals that received [pharmacogenetically] guided antidepressant treatment were 41% (95% CI: 15% – 74%) more likely to achieve depressive symptom remission relative to their counterparts who received treatment as usual.” [Brown]
The article analyzed ten randomized trials with a total of 2614 subjects. In addition, the analysis covers three unblinded studies with a total of 2153 subjects.
Last month, a systematic review of the cost-effectiveness of pharmacogenetics was also published. Regarding depression, the review states: “Nine out of 11 articles evaluating antidepressants were found to be cost effective or cost saving.”[Morris]
One of the articles in the review reviews:”Overall 6-month costs were estimated to be $1,948 (SE 611) lower in the tested group.”[Perlis]
[Brown] Brown, Lisa C., et al. “Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta‐Analysis of Prospective, Controlled Clinical Trials.” Clinical Pharmacology & Therapeutics(2022). https://doi.org/10.1002/cpt.2748
[Morris] Morris, Sarah A., et al. “Cost effectiveness of pharmacogenetic testing for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines: a systematic review.” Clinical Pharmacology & Therapeutics (2022). https://doi.org/10.1002/cpt.2754
[Perlis] Perlis, Roy H., et al. “Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity‐score matched study.” Depression and anxiety35.10 (2018): 946-952. https://doi.org/10.1002/da.22742
